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Abstract
Background: The interaction between viral oncoproteins such as Simian virus 40 TAg, adenovirus E1A, and human 
papilloma virus E7, and the retinoblastoma protein (pRB) occurs through a well characterized peptide sequence, 
LXCXE, on the viral protein and a well conserved groove in the pocket domain of pRB. Cellular proteins, such as histone 
deacetylases, also use this mechanism to interact with the retinoblastoma protein to repress transcription at cell cycle 
regulated genes. For these reasons this region of the pRB pocket domain is thought to play a critical role in growth 
suppression.
Results: In this study, we identify and characterize a tumor derived allele of the retinoblastoma gene (RB1) that 
possesses a discrete defect in its ability to interact with LXCXE motif containing proteins that compromises proliferative 
control. To assess the frequency of similar mutations in the RB1 gene in human cancer, we screened blood and tumor 
samples for similar alleles. We screened almost 700 samples and did not detect additional mutations, indicating that 
this class of mutation is rare.
Conclusions: Our work provides proof of principal that alleles encoding distinct, partial loss of function mutations in 
the retinoblastoma gene that specifically lose LXCXE dependent interactions, are found in human cancer.
Background
The RB1 gene was first identified based on its mutation in
retinoblastoma [1,2], however, it has since been found to
be absent or misregulated in almost all human cancers
[3]. The retinoblastoma protein (pRB) is also thought to
be an essential target for inactivation in cancer because it
is targeted by viral oncogenes during cellular transforma-
tion. The TAg protein product of Simian virus 40, E1A
from adenovirus, and E7 from human papilloma virus all
contain an LXCXE peptide motif that is essential for
transforming activity and it is used to contact the pocket
domain of pRB [4-6]. A number of cellular proteins, most
notably chromatin regulators such as histone deacety-
lases and methyltransferases, also use an LXCXE motif to
interact with pRB to participate in cell cycle regulation
[7]. We have previously mutagenized the pRB pocket
domain to map protein interaction sites and these results
have been published [8-10]. This work revealed that dis-
crete mutations in RB1, that only affect LXCXE interac-
tions and not E2Fs, are limited to the coding region of
exons 21 and 22 (Fig. 1). This is likely because the amino
acids encoded by these exons are in close proximity in the
three dimensional structure of the pRB pocket domain
[11]. Others have also reported that the C-terminal
region of pRB, that is phosphorylated by Cyclin/CDKs,
can interact with and regulate access to the LXCXE bind-
ing cleft [12]. This region is encoded by exon 23. Based on
these data we hypothesized that cancer derived mutant
alleles of human RB1 in these three exons have the poten-
tial to specifically disrupt LXCXE-type interactions in
isolation from other interactions with pRB's pocket
domain. Our work demonstrates the existence of this
class of mutation in human cancer. We also provide evi-
dence that this type of mutation can compromise pRB's
ability to regulate proliferation even when heterozygous
with a wild type copy of the retinoblastoma gene. * Correspondence: fdick@uwo.ca
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Results and Discussion
To determine if pRB-LXCXE disrupting mutations arise
in human cancer we initially searched the Retinoblastoma
Genetics Database [13] and the Catalogue of Somatic
Mutations in Cancer (COSMIC) database [14]. A number
of missense mutations have been identified that are found
in exons 21, 22 or 23 and we have generated expression
constructs for them to enable further study (Fig. 1). Addi-
tional mutations in these exons exist beyond what we
report here. However, they have either been previously
characterized, appear to be redundant with mutations
that we are studying, or are alleles that are very similar to
those tested in our previous alanine scanning experi-
ments. For example, the C706F variant found in small cell
lung cancer [15] has been well-characterized in previous
studies, and while it is unable to interact with LXCXE
proteins, it is also incapable of interacting with E2F tran-
scription factors, among other defects [16-19]. Further-
m o r e ,  w e  e x p e c t  t h a t  i t  i s  v e r y  s i m i l a r  t o  t h e
retinoblastoma derived C706Y mutant. Based on this rea-
soning, the mutations listed in Fig. 1 were selected for use
in this study because they are unique and uncharacter-
ized. Mutant proteins containing these substitutions were
tested for their ability to bind to LXCXE proteins, such as
TAg, as a marker for LXCXE-dependent interactions
(data not shown). Of the mutants tested, only M704V
showed properties similar to the pRBΔL mutant protein
that we generated based on crystallographic data to spe-
cifically disrupt this interaction (the ΔL mutant contains
I753A, N757A, and M761A substitutions). The proper-
ties of the M704V protein are revealed in experiments
using both GST-pulldown and immunoprecipitation
approaches (Fig. 2A &2B). Like pRBΔL, pRBM704V retains
the ability to interact with E2F3/DP1, but its ability to
interact with SV40-TAg is greatly compromised. The
similarity in specificity between our synthetic mutant
pRBΔL and the cancer derived M704V variant is likely
explained by the close proximity of the substituted amino
acids in the crystal structure of the pRB pocket [11]. In
addition to alterations in structure, mutations can also
cause proteins to lose function due to a decrease in pro-
tein stability. To examine this possibility, cells expressing
wild-type pRB, pRBΔL  or pRBM704V  were treated with
cycloheximide to block de novo protein synthesis. Cells
were harvested every 3 hours after treatment for 15 hours
and probed for pRB to monitor rates of protein degrada-
tion (Fig. 2C). The RBM704V protein showed similar stabil-
ity to wild type pRB and pRBΔL, with a half-life ranging
from 10 to 12 hours across a number of experiments,
which is comparable to previous publications [20,21].
Taken together, our data suggests that the pRBM704V
mutant has a specific defect for LXCXE interactions and
is stably expressed.
In the initial report of the M704V variant of pRB, it was
described as heterozygous [22]. Given that the retinoblas-
toma gene is thought to be functional until loss of
heterozygosity removes the remaining wild type allele, we
wondered how much the M704V mutant contributed to
the pathogenesis of the tumor where it was found. To
address the effects of heterozygosity of the M704V allele,
we took advantage of a gene targeted, knock in mouse
strain that possesses an analogous allele in its mouse RB1
Figure 1 Schematic diagram of the pRB open reading frame and corresponding exon structure of the RB1 gene. Candidate mutations in ex-
ons 21, 22, and 23 that were examined in this study are shown.Henley et al. Cancer Cell International 2010, 10:8
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gene (called Rb1ΔL). There are several advantages to using
a targeted knock in model over cell culture systems. Ini-
tial characterization of the pRBΔL mutant revealed sur-
prisingly few effects in cell culture assays; the mutant
protein maintained its ability to induce a cell cycle arrest
in RB1 deficient Saos2 cells as well as its ability to repress
E2F target genes [8]. This was unexpected because the
LXCXE binding cleft region of pRB is highly conserved
and confers susceptibility to viral pathogens, suggesting
that it must have an important function. T o circumvent
the limitations of cell culture systems, further studies
were performed in fibroblast cells from Rb1ΔL  mice.
Using these cells, discrete defects in pRBΔL's ability to
control the cell cycle were identified. More specifically,
disruption of LXCXE interactions in vivo abrogates G1
arrest in response to exogenous stimuli such as DNA
damage or transforming growth factor-β(TGF-β), but
does not speed up G1-S phase progression in proliferat-
ing cultures of cells [23-25]. For these reasons, we tested
the response of Rb1?/?,  Rb1ΔL/? and Rb1ΔL/ΔL  primary
embryonic fibroblasts to TGF-β treatment. In this way we
could carefully examine gene-dosage effects of the
Rb1ΔLmutant on growth arrest in an otherwise normal
cell. First, we tested the stability of the Rb1ΔL allele in vivo,
and found that the steady state levels of pRB in both
Rb1ΔL/? and Rb1ΔL/ΔL cells were similar to wild-type, con-
firming that this mutation does not affect protein stability
(Fig. 3A). Cells were then treated with TGF-β for 24
hours, pulse labelled with bromodeoxyuridine (BrdU),
and the percentage of BrdU positive cells was quantified
by flow cytometry (Fig. 3B). While the Rb1?/? fibroblasts
exhibited a marked decrease in proliferation in response
Figure 2 The pRBM704V protein is defective for LXCXE-dependent 
interactions. (A) The ability of wild type or mutant forms of GST-RB to 
interact with TAg or E2F3/DP1 was determined by pull-down experi-
ments. The input level of GST-RB proteins was determined by coo-
massie staining of SDS-PAGE gels, and the quantity of TAg or HA-E2F3/
HA-DP1 that was precipitated with GST-RB was detected by western 
blotting. (B) Interactions were also assessed by co-immunoprecipita-
tion of pRB with TAg or HA-E2F3/HA-DP1 proteins. In each case, the 
quantity of pRB present in precipitated complexes was determined by 
western blotting. UT indicates extracts that were generated from un-
transfected cells. (C) RB1 deficient cells transfected with wild type or 
mutant pRB were treated with cycloheximide, harvested at the indicat-
ed time points, and the quantity of pRB present was determined by 
western blotting.
Figure 3 Defective TGF-β growth arrest in Rb1ΔL/? fibroblasts. (A) 
The level of pRB expression was measured in Rb1?/?, Rb1ΔL/? and Rb1ΔL/
ΔL fibroblasts by western blotting. The upper blot shows pRB expres-
sion in these extracts and the lower blot shows Actin as a loading con-
trol. (B) All cells were treated with TGF-β for 24 hours, pulse labelled 
with BrdU for 1.5 hours and analyzed for incorporation by flow cytom-
etry to determine the percentage of positive cells. The mean percent-
age of BrdU positive cells was determined from three independently 
treated cultures of cells. Means were compared between genotypes 
using a t-test and were found to be statistically significant (* P < 0.05).Henley et al. Cancer Cell International 2010, 10:8
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to TGF-β treatment, both the Rb1ΔL/? and the Rb1ΔL/ΔL
cells displayed resistance to TGF-β growth arrest. Pair
wise comparisons of the percentage of BrdU positive cells
following TGF-β treatment between each genotype indi-
cates that they are significantly different (t-test, P < 0.05).
This reveals that loss of LXCXE interactions by even a
single Rb1 allele significantly reduces TGF-β growth inhi-
bition. The ability of the Rb1ΔL mutation to confer resis-
tance to TGF-β 's cytostatic effect is highly suggestive
that the M704V variant of pRB can contribute to cancer
susceptibility because even when heterozygous, muta-
tions that disrupt LXCXE interactions compromise pRB's
ability to regulate proliferation.
The mammary specific growth control defects in
Rb1ΔL/ΔL mice [24], along with the origin of the M704V
variant, suggest that ΔL-like mutations may be found in
breast and ovarian cancers. The connection between
breast and ovarian cancer is well known and the require-
ment for LXCXE interactions in TGF-β growth arrest
further suggests a link between this type of mutation and
these cancers. Indeed, two recent studies suggest that as
yet unidentified allelic variants of RB1 may modify the
risk of breast and ovarian cancer [26,27]. For these rea-
sons, we sought to identify more alleles of this type from
breast and ovarian cancer patients. To search for these
alleles, we devised a high resolution melting (HRM) assay.
HRM is a highly sensitive method that uses the distinct
melting curves of each region of DNA to identify
sequences that differ from a known standard. Again, the
t a r g e t  o f  t h i s  a n a l y s i s  w a s  RB1  exons 21, 22, and 23
because they can be altered to create alleles like M704V.
To test the sensitivity of HRM at this locus, primers were
designed to amplify each exon individually and plasmid
constructs were generated that encode either exon 21, 22
or 23 with or without single base pair substitutions from
previously characterized RB1  mutations. To detect
heterozygous sequence changes in RB1, equal quantities
of the wild type and mutant version of each construct
were mixed, PCR amplified, and subjected to melting
analysis alongside human genomic DNA samples (Fig.
4A). When the melt profile is compared to wild type con-
trol DNA, a shift in the melting curve is observed. When
analyzed by Gene Scanning software, the control
heterozygous samples were readily distinguished in a dif-
ference plot, validating the sensitivity of this assay for
each exon (Fig. 4B). In total 627, genomic DNA samples
were analyzed, representing individuals classified as high
risk for inherited breast and/or ovarian cancer. To search
for mutations in primary tumor specimens, 50 breast and
21 ovarian tumor samples were obtained. These were
PCR amplified and directly sequenced using primers spe-
cific to each exon because they may be homozygous at
the RB1 locus and thus indistinguishable from wild type
in our HRM analysis. The results from both methods of
screening are summarized in Table 1. No new alleles were
detected by this approach.
Conclusions
In this study we sought to identify cancer-associated
mutations that specifically target the region of RB1
encoding the LXCXE binding cleft. In this way, our goal
was to search for distinct RB1 alleles that are compro-
mised for just one aspect of its function. We character-
ized an ovarian cancer derived variant of RB1  that
possesses biochemical properties that are comparable to
our previously published Rb1ΔL mutant allele. We also
showed that a single mutant allele of Rb1 can significantly
decrease the response to TGF-β mediated growth arrest,
indicating that the retinoblastoma gene displays haploin-
sufficiency for growth control. While we were unable to
find more examples of this type of allele, our work sug-
gests that cancer types that are characterized by resis-
tance to TGF-β growth arrest and maintain
heterozygosity for RB1 may possess this type of mutant
allele as a means of overcoming growth inhibitory mech-
anisms that limit tumor formation.
Table 1: Summary of mutation detection.
Blood samples Tumor samples
Breast Ovarian
Screened Mutations Screened Mutations Screened Mutations
E x o n  2 1 6 2 7 05 002 10
E x o n  2 2 6 2 7 05 002 10
E x o n  2 3 6 2 7 05 002 10
To detect heterozygous sequence changes, peripheral blood samples from breast and/or ovarian cancer patients were subjected to HRM 
analysis using primers specific to exons 21, 22 and 23. To detect potentially homozygous sequence changes from breast and ovarian tumor 
samples, PCR amplicons of these exons were directly sequenced.Henley et al. Cancer Cell International 2010, 10:8
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Methods
Protein interaction analysis
Glutathione S-transferase (GST) pull-down experiments
were performed as described in Dick et al. [8]. The GST-
RB constructs contain the large pocket of pRB, encom-
passing amino acids 379 to 928. The GST-RBΔL and GST-
RBM704V contain I753A, N757A and M761A or M704V
substitutions, respectively. In each case, recombinant
proteins (or GST as a control) were incubated with
whole-cell extracts from C33A cells transfected with
either CMV-HA-E2F3 and CMV-HA-DP1, or CMV-TAg.
Bound proteins were detected by western blotting using
12CA5 hybridoma supernatant for HA-tagged E2F3/DP1,
or mouse monoclonal antibody PAb419 (CalBiochem) for
SV40-TAg, followed by a peroxidase conjugated anti-
mouse IgG secondary antibody. Input levels of GST-
fusions were detected by Coomassie staining.
Immunoprecipitations were performed essentially as
described in Siefried et al. [28]. The pRB constructs
tested contain either the full-length wild type RB1 cDNA
(CMV-RB) or RB1 cDNA that has been mutated to create
the desired amino acid substitutions (CMV-RBΔL  and
CMV-RBM704V). In brief, C33A cells were transfected
w i t h  1 0  μ g  o f  e a c h  C M V - R B  c o n s t r u c t  i n  a d d i t i o n  t o
either 5 μg of CMV-TAg or 5 μg each of CMV-HA-E2F3
and CMV-HA-DP1. To precipitate TAg immune com-
plexes, the PAb419 antibody (CalBiochem) was used,
whereas 12CA5 hybridoma supernatant was used to pull
down HA-containing immune complexes. In each case,
bound pRB was detected by western blotting using the
G3-245 α-pRB antibody (BD Pharmingen), as above. HA-
E2F3, HA-DP1 and TAg input levels were also detected
by western blotting.
Protein stability assay
To assess protein stability, 2.6 × 106 C33A cells were
transfected by Ca2PO4 with 45 μg of CMV-RB, CMV-
RBΔL or CMV-RBM704V in a 15 cm plate. Twenty-four
hours post-transfection cells were replated into 6 repli-
cate 6 cm plates. Twenty-four hours after replating, cells
were treated with 100 μg/mL cycloheximide and har-
vested after 0, 3, 6, 9, 12 and 15 hours. To detect pRB, 10
μg of total protein was analyzed by western blotting as
described above. Protein levels were quantified by densi-
tometry using a Bio Rad Gel Doc XR gene imager and
half-lives were calculated accordingly. To assess the
expression of pRB in vivo, asynchronously proliferating
Rb1?/?, Rb1ΔL/? and Rb1ΔL/ΔL MEFs were harvested and 50
μg of total protein was analyzed by western blotting using
the Rb1 4.1 hybridoma, followed by a peroxidase conju-
gated anti-mouse IgG secondary antibody. The hybri-
doma developed by Julien Sage was obtained from the
Developmental Studies Hybridoma Bank developed
under the auspices of the NICHD and maintained by The
University of Iowa, Department of Biology, Iowa City, IA
52242.
TGF-β growth arrest assays
Asynchronously proliferating Rb1?/?, Rb1ΔL/? and Rb1ΔL/ΔL
MEFs were treated with 100 pM TGF-β1 (R&D systems)
for 24 hours. Cells were then pulse labelled with BrdU
Figure 4 High resolution melting analysis of RB1 exons 21, 22 and 
23. (A) To detect heterozygous sequence changes in RB1, constructs 
were created that encode either exon 21, 22 or 23 with or without sin-
gle base pair substitutions. Equal quantities of these constructs were 
mixed, PCR amplified, and subjected to melting analysis alongside hu-
man genomic DNA samples. (B) Each DNA sample was analyzed in du-
plicate and the differences in melting profiles are plotted as a 
normalized difference plot. Representative difference plots for each 
exon are shown. In each case the pair of heterozygous plasmid con-
trols (shown in red) is readily distinguishable from the homozygous 
human samples (shown in blue) by the Gene Scanning software as it 
assigns the colours.Henley et al. Cancer Cell International 2010, 10:8
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(RPN201V1, Amersham Biosciences) for 1.5 hours. BrdU
incorporation was quantified using flow cytometry on a
Beckman-Coulter EPICS XL-MCL instrument, as previ-
ously described [29].
Patient samples
Peripheral blood DNA samples (627 specimens) from
human breast and/or ovarian cancer patients were
o b t a i n e d  f r o m  t h e  L o n d o n  H e a l t h  S c i e n c e s  C e n t r e ,
Molecular Diagnostics Laboratory (London, ON). All
samples were post-testing material from individuals that
meet Ontario provincial referral criteria because they are
under the age of 35 (173), have three or more cases of
breast or ovarian cancer on the same side of the family
(155) or otherwise have a pedigree that is strongly sugges-
t i v e  o f  h e r e d i t a r y  b r e a s t / o v a r i a n  c a n c e r .  F r o z e n  b r e a s t
tumor samples were obtained from the Ontario Tumour
Bank. Samples were chosen at random (not based on his-
tological characteristics) from patients between 38 and 87
years of age. All tumor material was derived from the pri-
mary site. DNA was isolated from these samples using
standard techniques. DNA from ovarian tumor samples
was prepared from passage two cells that were isolated
from patient ascites. Ovarian samples were from patients
between 25 and 85 years of age. DNA was provided cour-
tesy of the Translational Ovarian Cancer Program at the
London Health Sciences Centre.
High resolution melting (HRM) analysis
HRM analysis was conducted using the Roche Lightcy-
cler 480 HRM kit. In brief, each 20 μL reaction consisted
of 10 μL of 2× Master Mix, 0.1875 μM of each primer, 3.0
to 4.0 mM of MgCl2 and 50 ng of genomic DNA. As a
positive control, test constructs encoding individual
exons with either a single nucleotide change (mutant) or
without (wild type) were mixed in equal quantities and
0.1 pg of the resulting mixture was used in place of a
genomic DNA sample. The mutant constructs for exon
21 and exon 22 each contain a single G to T substitution
(g.160839G>T and g.162027G>T) from previously
reported cancer-causing RB1  alleles [30], whereas the
construct for exon 23 contained a previously reported C
to G substitution (g.162241G>C)[31]. To amplify each
exon the following primer pairs were used: exon 21 cag-
tatggaaagaaataactctgtag and gtgaatttacataataaggtcaga-
cag, exon 22 gcccccgccgttactgttcttcctcagacattcaa and
cccccgcccgaatgttttggtggacccatt and exon 23 gcggcccgc-
cgcccccgccgcttccaccagggtaggtcaa and
gccgggcgcgcccccgcccgggatcaaaataatccccctctcat. The
amplification and melt analysis were conducted sequen-
tially in the Roche Lightcycler 480. First, samples were
incubated at 95°C for 10 minutes, followed by 50 cycles
of: 95°C for 10 seconds, a touch down of 65 to 55°C (exon
21) or 70 to 65°C (exons 22 and 23) for 20 seconds, 72°C
for 10 seconds. The samples were then heated to 95°C to
generate a melt curve. All samples were run in duplicate
and each plate contained duplicate positive controls.
Lightcycler 480 Gene Scanning software was used to nor-
malize the data and generate difference plots.
Sequencing
To detect sequence changes in tumor DNA samples, PCR
products were generated and directly sequenced (McGill
University and Genome Quebec Innovation Centre).
Exon 21 products were obtained and sequenced using
primers 21F (ttgggttaaacacttcatgtagac) and 21R (cctatgt-
tatgttatggatatggatt). Exons 22 and 23 were amplified in a
single reaction using primers 22F (tataatatgtgcttcttacca-
gtcaa) and 23R (aagcaaatatgagtttcaagagtctagc) and
sequenced using primers 22F and 23R2 (gcgttgcttaagtcg-
taaatagatt).
Abbreviations
pRB: retinoblastoma protein; RB1: human retinoblastoma gene; Rb1: murine
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